Blood tests could tailor leukemia therapy for older patients
NCT ID NCT06030089
First seen Jan 03, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study looked at 20 adults with acute myeloid leukemia (AML) who cannot have strong chemotherapy. They received a standard drug combination (azacitidine + venetoclax). Researchers measured venetoclax levels in the blood to see if they relate to how well the drug works and its side effects. The goal is to learn how to personalize dosing for each patient in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nice
Nice, France
-
Hopital la Conception
Marseille, France
Conditions
Explore the condition pages connected to this study.